ClinicalTrials.gg
CompletedNCT03398538Updated Aug 3, 2022

Resorbable Glass Fiber Matrix in the Treatment of Diabetic Foot Ulcers

An interventional study of Offloading and Additional (outer) Dressing Application in Diabetic Foot Ulcer, Ulcer Foot and Diabetic Foot, sponsored by ETS Wound Care, LLC. Completed at 5 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-08-03.

Sponsored by ETS Wound Care, LLC · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is a prospective, multi-center, randomized controlled trial designed to collect patient outcome data on 2 commercially available SOC dressings treatments for Diabetic Foot Wounds

Read the detailed description

This study is a prospective, multi-center, RCT designed to collect patient outcome data on two commercially available SOC treatments for DFUs. The trial will be single blinded in regard to wound healing assessment (another clinician, other than the investigator at each site will assess wound healing) and confirmation of wound healing will be overseen by an independent adjudication committee made up of wound care experts. The study will last twelve weeks, with a two week screening period prior to enrollment.

There are two standard of care arms in the study:

Arm 1: The SOC therapy in this study is offloading of the DFU (CAM boots or total contact casting [TCC] if the subject's foot is too large for a CAM), appropriate sharp or surgical debridement, infection management (systemic antibiotics only in conjunction with debridement) and wound care covering with bioactive resorbable glass fiber dressing, MIRRAGEN™Advanced Wound Matrix, followed by a padded 3-layer dressing comprised of 4x4 gauze pads, soft roll and compressive wrap (DynaflexTM or equivalent).

Arm 2: The SOC therapy in this study is offloading of the DFU (CAM boots or total contact casting [TCC] if the subject's foot is too large for a CAM), appropriate sharp or surgical debridement, infection management (systemic antibiotics only in conjunction with debridement) and wound care covering with calcium alginate Fibracol dressing followed by a padded 3-layer dressing comprised of 4x4 gauze pads, soft roll and compressive wrap (DynaflexTM or equivalent).

02

Conditions studied

  • Diabetic Foot Ulcer
  • Ulcer Foot
  • Diabetic Foot

Keywords

  • DFU
  • Ulcer
03

In context

Diabetic Foot

1,077 studies on the registry are indexed under Diabetic Foot; 222 are open to participants now.

This study's enrollment of 40 is below the median of 60 across 847 interventional studies indexed under Diabetic Foot.

Browse Diabetic Foot studies →

Lead sponsor

ETS Wound Care, LLC is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 18 years old.
  • Presence of a DFU, Wagner 1 (see Appendix B for definitions), extending at least through the dermis provided it is below the medial aspect of the malleolus.
  • The index ulcer will be the largest ulcer if two or more DFUs are present with the same Wagner grade and will be the only one evaluated in the study. If other ulcerations are present on the same foot they must be more than 2 cm distant from the index ulcer.
  • Index ulcer (i.e. current episode of ulceration) has been present for greater than 4 weeks prior to SV1 and less than 1-year, as of the date the subject consents for study.
  • Index ulcer is a minimum of 1.0 cm2 and a maximum of 25 cm2 at SV1 and TV1.
  • Adequate circulation to the affected foot as documented by a dorsal transcutaneous oxygen measurement (TCOM) or a skin perfusion pressure (SPP) measurement of ≥ 30 mmHg, or an Ankle Branchial Index (ABI) between 0.7 and 1.3 within 3 months of SV1, using the affected study extremity. As an alternative arterial Doppler ultrasound can be performed evaluating for biphasic dorsalis pedis and posterior tibial vessels at the level of the ankle or a Toe Brachial Index (TBI) of > 0.6 is acceptable.
  • The target ulcer has been offloaded for at least 14 days prior to randomization.
  • Females of must be willing to use acceptable methods of (birth control pills, barriers or abstinence) during the course of the study and undergo pregnancy tests.
  • Subject understands and is willing to participate in the clinical study and can comply with weekly visits.

Exclusion criteria

Exclusion Criteria:

  • Index ulcer(s) deemed by the investigator to be caused by a medical condition other than diabetes.
  • Index ulcer, in the opinion of the investigator, is suspicious for cancer and should undergo an ulcer to rule out a carcinoma of the ulcer.
  • Subjects with a history of more than two weeks treatment with immune-suppressants (including systemic >10mg daily dose), cytotoxic chemotherapy, or application of topical steroids to the ulcer surface within 1-month prior to first SV1, or who receive such medications during the screening period or who are anticipated to require such medications during the course of the study.
  • Subjects taking a selective COX-2 inhibitor, such as Celecoxib, for any condition.
  • Subjects on any drug(s) or therapeutic device(s) within 30 days preceding SV1.
  • History of radiation at the ulcer site (regardless of time since last radiation treatment).
  • Index ulcer has been previously treated or will need to be treated with any prohibited therapies. (See Section 7.3 of this protocol for a list of prohibited medications and therapies).
  • Presence of any condition(s) which seriously compromises the subject's ability to complete this study or has a known history of poor adherence with medical treatment.
  • Osteomyelitis or bone infection of the affected foot as verified by x-ray within 30 days prior to randomization. (In the event of an ambiguous diagnosis, the Principal Investigator will make the final decision).
  • Subject is pregnant or breast-feeding.
  • Presence of diabetes with poor metabolic control as documented with an > 12.0 within 90 days of randomization.
  • Subjects with end stage renal disease as evidenced by a serum creatinine ≥ 3.0 mg/dL within 6 months of randomization.
  • Index ulcer has reduced in area by 20% or more after 14 days of SOC from SV1 to the TV1/randomization visit.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Mirragen Wound Matrix Dressing

    MIRRAGEN™ Advanced Wound Matrix is intended for the use in the management of wounds including diabetic ulcers. Wound matrix dressing to be used per manufacturer instructions for use on diabetic foot wounds in conjunction with offloading and Additional (outer) Dressing Application with moisture retention dressing

    Other: Offloading · Other: Additional (outer) Dressing Application · Other: Mirragen Wound Matrix Dressing

  • Active comparator
    Fibracol Wound Dressing

    A commercially available wound dressing to be used per manufacturer's instructions for use on diabetic foot wounds in conjunction with offloading and Additional (outer) Dressing Application with moisture retention dressing moisture retention dressing

    Other: Offloading · Other: Additional (outer) Dressing Application · Other: Fibracol Wound Dressing

Interventions

  • OtherOffloading

    Patient will be offloaded in a diabetic camboot after treatment, or total contact cast if patient cannot be fit with diabetic offloading boot

    Also known as: Pressure relief

  • OtherAdditional (outer) Dressing Application

    Application of outer a moisture retentive dressing, and a multi-layer compression dressing.

    Also known as: Outer protective dressing

  • OtherMirragen Wound Matrix Dressing

    Application of Mirragen to wound site along with standard of care treatment

  • OtherFibracol Wound Dressing

    Application of Fibracol Alginate along with standard of care treatment

06

What researchers measure

Primary outcomes

  1. Percentage of index ulcers healed at 12 weeks

    examine percent of ulcers healed at week twelve

    Time frame: 12 weeks

Secondary outcomes

  1. Percentage of index ulcers healed at 6 weeks

    examine percent of ulcers healed at week six

    Time frame: 6 week

  2. Time to heal within 6 and 12 weeks

    examine time to healing at both six and twelve weeks

    Time frame: 6 and 12 weeks

  3. Percent Area Reduction (PAR) at 6 and 12 weeks

    examine PAR at both six and twelve weeks

    Time frame: 6 and 12 weeks

  4. Changes in peripheral neuropathy using Semmes Weinstein Monofilament "10"point discrimination test

    Each clinical trial participant will be examined by the principal investigator with a Semmes Weinstein monofilament wire at 10 points on the study foot, this standardized exam will be scored out of a total of 10 at each visit and recorded

    Time frame: 12 weeks

  5. Changes in wound quality of life, the " Wound Quality of Life Questionnaire" will be given to the clinical trial participants and administered during each visit

    The Wound-QoL, or wound quality of life questionnaire, measures the disease-specific, health-related quality of life of patients with chronic wounds. It consists of 17 items on impairments which are always assessed in retrospect to the preceding seven days. This questionnaire will be given to clinical trial participants at each visit, with the scale scores recorded. Each question is scored. Answers to each item are coded with numbers (0='not at all' to 4='very much'). As noted above the score will be reported with a minimam score of "0" and a maximum score of 68

    Time frame: 12 weeks

  6. Change in pain levels during trial, using the FACES pain scales which measure pain on a range of 0-10, zero being no pain and 10 being the most severe pain

    The FACES pain scale will be administered to the clinical trial participants at each visit. The trial participant will select their pain level with a series of faces that correspond to a number between 0 which implies no pain , up to 10 which implies the most severe pain. The scores will be recorded for each clinical trial participant on each visit

    Time frame: 12 weeks

  7. Difference in cellulitis and/or infection at 12 weeks

    Examine difference in infection rate over twelve weeks

    Time frame: 12 weeks

07

Study locations

5 sites
  • Alan M Jacobs and Associates
    Saint Louis, Missouri 63117, United States
  • Lower Extremity Institute of Research and Therapy
    Youngstown, Ohio 44512, United States
  • Martinsville Research Institute
    Martinsville, Virginia 23116, United States
  • Professional Education and Research Institute
    Roanoke, Virginia 24016, United States
  • Shenandoah Lower Extremity Research Institute
    Troutville, Virginia 24019, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 3, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03398538
Lead sponsor
ETS Wound Care, LLC
Collaborators
Professional Education and Research Institute
Responsible party
Sponsor
First posted
Jan 12, 2018
Start date
Dec 26, 2017
Primary completion
Oct 31, 2018
Completion
Oct 31, 2018
Last update
Aug 3, 2022

Study contacts

David Armstrong, DPM, MD, PhD
principal investigator · USC / Salsa
Charles M Zelen, DPM
principal investigator · Professional Education and Research Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion